<DOC>
	<DOC>NCT00111800</DOC>
	<brief_summary>This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.</brief_summary>
	<brief_title>A New Oral Treatment For Type II Diabetes Mellitus</brief_title>
	<detailed_description>A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of GW823093, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a 12-week Active Treatment Extension</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion criteria: Women must not be pregnant and must not be breastfeeding. Have Type II diabetes. Not taking any medicine for diabetes, or taking one oral medicine for their diabetes. Exclusion criteria: Have any underlying or significant active disease that would prevent the subject from safely participating in the trial by the judgement of the study doctor.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NIDDM</keyword>
</DOC>